首页> 外文期刊>Multiple sclerosis: clinical and laboratory research >No evidence of an increased risk for malignancy associated with natalizumab therapy in 9 years of postmarketing surveillance

【24h】

No evidence of an increased risk for malignancy associated with natalizumab therapy in 9 years of postmarketing surveillance

机译：没有证据表明在上市后9年中与那他珠单抗治疗相关的恶性肿瘤风险增加

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Multiple sclerosis: clinical and laboratory research》 |2016年第6期|共2页
作者
Carrillo-Infante Cynthia; Gheuens Sarah; Wenten Made; Ho Pei-Ran; Koulinska Irene; Richman Sandra;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词

相似文献

外文文献
中文文献
专利

1. No evidence of an increased risk for malignancy associated with natalizumab therapy in 9 years of postmarketing surveillance [J] . Carrillo-Infante Cynthia, Gheuens Sarah, Wenten Made, Multiple sclerosis: clinical and laboratory research . 2016,第6期

机译：没有证据表明在上市后9年中与那他珠单抗治疗相关的恶性肿瘤风险增加
2. Multiple primary malignancies in patients with prostate cancer: Increased risk of secondary malignancies after radiotherapy [J] . OkajimaK., IshikawaK., MatsuuraT., International journal of clinical oncology . 2013,第6期

机译：前列腺癌患者的多发原发性恶性肿瘤：放疗后继发性恶性肿瘤的风险增加
3. Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced Malignancy [J] . Meyer Carlos, Millan Pablo, Gonzalez Valeria, Clinical breast cancer . 2019,第3期

机译：乳腺癌幸存者的密集成像监测可能会增加辐射诱导的恶性肿瘤的风险
4. Analysis of Twitter Data for Postmarketing Surveillance in Pharmacovigilance [C] . Julie Pain, Jessie Levacher, Adam Quinquenel, Workshop on noisy user-generated text . 2016

机译：用于药物警戒的上市后监视的Twitter数据分析
5. Predictors of colorectal cancer surveillance among survivors of childhood cancer at high risk for subsequent colorectal malignancies. [D] . Daniel, Casey L. 2013

机译：儿童癌症幸存者中结直肠癌监测的预测因素，其随后发生结直肠恶性肿瘤的风险很高。
6. Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data [O] . Gary Bloomgren, Bjørn Sperling, Kimberly Cushing, 2012

机译：肌内干扰素β-1a治疗的多发性硬化症患者的恶性风险评估：使用健康保险理赔数据库和上市后监测数据的回顾性评估
7. Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data [O] . Bloomgren, Gary, Sperling, Bjørn, Cushing, Kimberly, 2012

机译：肌内干扰素β-1a治疗的多发性硬化症患者的恶性风险评估：使用健康保险理赔数据库和上市后监测数据的回顾性评估
8. Postmarketing Surveillance of Toxicities Associated with Cancer Chemotherapy. Inclusive Dates: 04/01/07 - 03/31/12. [R] . Du, X. L. 2012

机译：上市后对癌症化疗相关毒性的监测。包容性日期：04/01/07 - 03/31/12。

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号